HENGRUI PHARMA Gains Approval to Launch Clinical Trial of SHR-1139 Injection

Stock News11-09

HENGRUI PHARMA (01276) has issued an announcement stating that recently, Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as "the Company"), received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (hereinafter referred to as "NMPA") for SHR-1139 injection, and will soon commence clinical trials.

SHR-1139 injection is a dual-specific antibody independently developed by the Company that simultaneously targets IL-23p19 and IL-36R, blocking both pathways at once and potentially providing more comprehensive and durable inflammation control.

According to available information, no comparable drug has been approved for marketing either domestically or internationally to date. As of now, the cumulative R&D investment in SHR-1139 injection and related projects amounts to approximately RMB 162.70 million (unaudited).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment